Silver Book Fact

Targeting A-type K+ channels in primary sensory neurons could provide a novel mechanism-based therapy for the treatment of bone cancer pain–one of the most severe types of chronic pain.

Duan K, Xu Q, Zhang X, Zhao Z, et al. Targeting A-Type K+ Channels in Primary Sensory Neurons for Bone Cancer Pain in a Rat Model. Pain. 2012; 153(3): 562-74. http://www.ncbi.nlm.nih.gov/pubmed/22188869

Reference

Title
Targeting A-Type K+ Channels in Primary Sensory Neurons for Bone Cancer Pain in a Rat Model
Publication
Pain
Publication Date
2012
Authors
Duan K, Xu Q, Zhang X, Zhao Z, et al.
Volume & Issue
Volume 153, Issue 3
Pages
562-74
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Pain education programs and pain consultations have been found to improve pain (average pain was 31% versus 20%) and daily interference (20% versus 2.5%) in oncology outpatients. Patient adherence…  
  • Antiepileptic drugs relieve persistent neuropathic pain. One meta-analysis found gabapentin to be associated with moderate benefit (equivalent to 30% pain relief) in close to 1 in 2 patients, and…  
  • Use of stem cells to create neurons could enable the study of the response of human cells to new drugs in vitro, early in the drug development process.  
  • The combination of information for neuroimaging and circulatory biomarkers could improve both the sensitivity and specificity of pain diagnosis and thereby improve treatment.  
  • Pregalbin, an antiepileptic drug, produced around a 32% pain reduction (a significant reduction) at week 16 versus around 20% for placebo, in patients with neuropathic pain due to spinal cord…